<![CDATA[#News #Recall #Medicine]]>

Vitruvias Therapeutics is recalling one lot of thyroid medication distributed nationwide after testing found the tablets could be more potent than intended, according to a recall notice published by the U.S. Food and Drug Administration (FDA).

The Auburn, Alabama-based company voluntarily recalled Lot 504950 of Thyroid Tablets, USP 30 mg at the consumer level because of the potential for the medication to be "superpotent."

]]>https://postcall.pub/topic/81f72375-da01-466e-acd0-a6d5043a0821/news-recall-medicineRSS for NodeSun, 30 Aug 2026 12:12:56 GMTWed, 26 Aug 2026 04:24:41 GMT60<![CDATA[Reply to #News #Recall #Medicine on Wed, 26 Aug 2026 18:48:37 GMT]]>@HopelessDemigod I already have all the above, except weight loss. Maybe I'll give thyroid tablets a shot.

]]>https://postcall.pub/post/https://c.im/users/darren/statuses/117163302424653181https://postcall.pub/post/https://c.im/users/darren/statuses/117163302424653181Wed, 26 Aug 2026 18:48:37 GMT<![CDATA[Reply to #News #Recall #Medicine on Wed, 26 Aug 2026 04:26:50 GMT]]>Taking superpotent thyroid tablets can cause hyperthyroidism, or an overactive thyroid, with symptoms that can include weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, rapid heart rate and heart rhythm disturbances, according to the company

The recalled product carries NDC 69680-166-00 and an expiration date of Sept. 30, 2026. The company released 3,655 units and reported 1,955 units sold.

EOF

]]>https://postcall.pub/post/https://mstdn.social/users/HopelessDemigod/statuses/117159913774121068https://postcall.pub/post/https://mstdn.social/users/HopelessDemigod/statuses/117159913774121068Wed, 26 Aug 2026 04:26:50 GMT